term=cmml
I see different drugs in the pipeline, including
Gleevec which is very successful in other blood cancers. I do see some monoclonal antibodies there. Aha, the bortezomib study is here:
http://clinicaltrials.gov/ct2/show/NCT00437086
But it was just a pilot, i.e., the very earliest stage of investigation. But that apparently showed it to be safe, as expected. IOW, it is not a risky last-chance drug. Neither most likely are none the MABs risky, they are very mild in side effects.